BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang W, Xia J, Xie S, Zou R, Pan S, Wang Z, Assaraf YG, Zhu X. Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. Drug Resistance Updates 2020;50:100683. [DOI: 10.1016/j.drup.2020.100683] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Xia L, Chen J, Huang M, Mei J, Lin M. The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression. Front Oncol 2022;12:963617. [DOI: 10.3389/fonc.2022.963617] [Reference Citation Analysis]
2 Gurnari C, Pagliuca S, Visconte V. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. Int J Mol Sci 2020;21:E8505. [PMID: 33198085 DOI: 10.3390/ijms21228505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pi YN, Qi WC, Xia BR, Lou G, Jin WL. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential. Front Immunol 2021;12:697083. [PMID: 34295338 DOI: 10.3389/fimmu.2021.697083] [Reference Citation Analysis]
4 Chen S, Chen C, Hu Y, Song G, Shen X. The diverse roles of circular RNAs in pancreatic cancer. Pharmacol Ther 2021;226:107869. [PMID: 33895187 DOI: 10.1016/j.pharmthera.2021.107869] [Reference Citation Analysis]
5 Ling B, Liao X, Tang Q, Ye G, Bin X, Wang J, Pang Y, Qi G. MicroRNA-106b-5p inhibits growth and progression of lung adenocarcinoma cells by downregulating IGSF10. Aging (Albany NY) 2021;13:18740-56. [PMID: 34351868 DOI: 10.18632/aging.203318] [Reference Citation Analysis]
6 Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
7 Li Z, Li X, Xu D, Chen X, Li S, Zhang L, Chan MTV, Wu WKK. An update on the roles of circular RNAs in osteosarcoma. Cell Prolif 2021;54:e12936. [PMID: 33103338 DOI: 10.1111/cpr.12936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
8 Hamid AB, Petreaca RC. Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers (Basel) 2020;12:E927. [PMID: 32283832 DOI: 10.3390/cancers12040927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kalhori MR, Khodayari H, Khodayari S, Vesovic M, Jackson G, Farzaei MH, Bishayee A. Regulation of Long Non-Coding RNAs by Plant Secondary Metabolites: A Novel Anticancer Therapeutic Approach. Cancers (Basel) 2021;13:1274. [PMID: 33805687 DOI: 10.3390/cancers13061274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Li R, Chen Z, Zhou Y, Maimaitirexiati G, Yan Q, Li Y, Maimaitiyimin A, Zhou C, Ren J, Liu C, Mainike A, Zhou P, Ding L. LncRNA SCAMP1 disrupts the balance between miR-26a-5p and ZEB2 to promote osteosarcoma cell viability and invasion. Front Oncol 2022;12:967000. [DOI: 10.3389/fonc.2022.967000] [Reference Citation Analysis]
11 Stanković T, Ranđelović T, Dragoj M, Stojković Burić S, Fernández L, Ochoa I, Pérez-García VM, Pešić M. In vitro biomimetic models for glioblastoma-a promising tool for drug response studies. Drug Resist Updat 2021;55:100753. [PMID: 33667959 DOI: 10.1016/j.drup.2021.100753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Guo C, Gong M, Li Z. Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a/EIF4E Axis. Cancer Manag Res 2020;12:5845-55. [PMID: 32765087 DOI: 10.2147/CMAR.S248698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Cohen L, Livney YD, Assaraf YG. Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist Updat 2021;56:100762. [PMID: 33857756 DOI: 10.1016/j.drup.2021.100762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Singh D, Khan MA, Siddique HR. Emerging role of long non-coding RNAs in cancer chemoresistance: unravelling the multifaceted role and prospective therapeutic targeting. Mol Biol Rep 2020;47:5569-85. [PMID: 32601922 DOI: 10.1007/s11033-020-05609-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Chen T, Liu J, Zhang H, Li J, Shang G. Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma. Front Oncol 2022;12:907472. [DOI: 10.3389/fonc.2022.907472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Akbari Dilmaghani N, Khoshsirat S, Shanaki-Bavarsad M, Pourbagheri-Sigaroodi A, Bashash D. The contributory role of long non-coding RNAs (lncRNAs) in head and neck cancers: Possible biomarkers and therapeutic targets? Eur J Pharmacol 2021;900:174053. [PMID: 33766619 DOI: 10.1016/j.ejphar.2021.174053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Xu H, Zhou W, Zhang F, Wu L, Li J, Ma T, Cao T, Lian C, Xia J, Wang P, Ma J, Li Y. PDS5B inhibits cell proliferation, migration, and invasion via upregulation of LATS1 in lung cancer cells. Cell Death Discov 2021;7:168. [PMID: 34226509 DOI: 10.1038/s41420-021-00537-6] [Reference Citation Analysis]
18 Hu Q, Egranov SD, Lin C, Yang L. Long noncoding RNA loss in immune suppression in cancer. Pharmacol Ther 2020;213:107591. [PMID: 32473960 DOI: 10.1016/j.pharmthera.2020.107591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
19 Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao P, Zhang L, Chen ZS, Zou C. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther 2020;5:193. [PMID: 32900991 DOI: 10.1038/s41392-020-00300-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
20 Chen D, Wang M, Jiang X, Xiong Z. Comprehensive analysis of ZFPM2-AS1 prognostic value, immune microenvironment, drug sensitivity, and co-expression network: from gastric adenocarcinoma to pan-cancers. Discov Oncol 2022;13:24. [PMID: 35416526 DOI: 10.1007/s12672-022-00487-0] [Reference Citation Analysis]
21 Li S, Tang M, Zen N, Liang J, Xing X, Huang D, Liu F, Zhang X. LncRNA OIP5-AS1 Knockdown Targets miR-183-5p/GLUL Axis and Inhibits Cell Proliferation, Migration and Metastasis in Nasopharyngeal Carcinoma. Front Oncol 2022;12:921929. [PMID: 35756672 DOI: 10.3389/fonc.2022.921929] [Reference Citation Analysis]
22 Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, Xie N. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol 2021;9:641469. [PMID: 33732706 DOI: 10.3389/fcell.2021.641469] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
23 Gianì F, Vella V, Tumino D, Malandrino P, Frasca F. The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer. Cancers (Basel) 2020;12:E2249. [PMID: 32796774 DOI: 10.3390/cancers12082249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Hu H, Xu H, Lu F, Zhang J, Xu L, Xu S, Jiang H, Zeng Q, Chen E, He Z. Exploring the Effect of Differentially Expressed Long Non-coding RNAs Driven by Copy Number Variation on Competing Endogenous RNA Network by Mining Lung Adenocarcinoma Data. Front Cell Dev Biol 2020;8:627436. [PMID: 33585468 DOI: 10.3389/fcell.2020.627436] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Wozniak M, Czyz M. The Functional Role of Long Non-Coding RNAs in Melanoma. Cancers (Basel) 2021;13:4848. [PMID: 34638331 DOI: 10.3390/cancers13194848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov 2021;20:629-51. [PMID: 34145432 DOI: 10.1038/s41573-021-00219-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
27 Cheng F, Liu J, Zhang Y, You Q, Chen B, Cheng J, Deng C. Long Non-Coding RNA UBA6-AS1 Promotes the Malignant Properties of Glioblastoma by Competitively Binding to microRNA-760 and Enhancing Homeobox A2 Expression. Cancer Manag Res 2021;13:379-92. [PMID: 33469379 DOI: 10.2147/CMAR.S287676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Xie W, Chu M, Song G, Zuo Z, Han Z, Chen C, Li Y, Wang ZW. Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer. Semin Cancer Biol 2020:S1044-579X(20)30222-4. [PMID: 33207266 DOI: 10.1016/j.semcancer.2020.11.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
29 Chen X, Liu Y, Liu H, Wang ZW, Zhu X. Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers. Pharmacol Ther 2022;238:108188. [PMID: 35421419 DOI: 10.1016/j.pharmthera.2022.108188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Izadirad M, Jafari L, James AR, Unfried JP, Wu ZX, Chen ZS. Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia. Drug Discov Today 2021;26:1735-43. [PMID: 33781951 DOI: 10.1016/j.drudis.2021.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat 2021;57:100770. [PMID: 34175687 DOI: 10.1016/j.drup.2021.100770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Singh D, Assaraf YG, Gacche RN. Long Non-coding RNA Mediated Drug Resistance in Breast Cancer. Drug Resistance Updates 2022. [DOI: 10.1016/j.drup.2022.100851] [Reference Citation Analysis]
33 Balihodzic A, Prinz F, Dengler MA, Calin GA, Jost PJ, Pichler M. Non-coding RNAs and ferroptosis: potential implications for cancer therapy. Cell Death Differ 2022;29:1094-106. [PMID: 35422492 DOI: 10.1038/s41418-022-00998-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Man X, Li Q, Wang B, Zhang H, Zhang S, Li Z. DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy. Front Cell Dev Biol 2022;10:916725. [PMID: 35620052 DOI: 10.3389/fcell.2022.916725] [Reference Citation Analysis]
35 Yao ZT, Yang YM, Sun MM, He Y, Liao L, Chen KS, Li B. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun (Lond) 2022. [PMID: 35019235 DOI: 10.1002/cac2.12254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
36 Iraola-Guzmán S, Brunet-Vega A, Pegueroles C, Saus E, Hovhannisyan H, Casalots A, Pericay C, Gabaldón T. Target Enrichment Enables the Discovery of lncRNAs with Somatic Mutations or Altered Expression in Paraffin-Embedded Colorectal Cancer Samples. Cancers (Basel) 2020;12:E2844. [PMID: 33019720 DOI: 10.3390/cancers12102844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Xu Y, Yu X, Zhang M, Zheng Q, Sun Z, He Y, Guo W. Promising Advances in LINC01116 Related to Cancer. Front Cell Dev Biol 2021;9:736927. [PMID: 34722518 DOI: 10.3389/fcell.2021.736927] [Reference Citation Analysis]
38 Li J, Guo S, Sun Z, Fu Y. Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor. Front Cell Dev Biol 2022;10:808591. [DOI: 10.3389/fcell.2022.808591] [Reference Citation Analysis]
39 Sellitto A, Pecoraro G, Giurato G, Nassa G, Rizzo F, Saggese P, Martinez CA, Scafoglio C, Tarallo R. Regulation of Metabolic Reprogramming by Long Non-Coding RNAs in Cancer. Cancers (Basel) 2021;13:3485. [PMID: 34298698 DOI: 10.3390/cancers13143485] [Reference Citation Analysis]
40 Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resist Updat 2021;:100796. [PMID: 34953682 DOI: 10.1016/j.drup.2021.100796] [Reference Citation Analysis]
41 Zheng C, Chu M, Chen Q, Chen C, Wang ZW, Chen X. The role of lncRNA OIP5-AS1 in cancer development and progression. Apoptosis 2022. [PMID: 35316453 DOI: 10.1007/s10495-022-01722-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wang J, Ma X, Si H, Ma Z, Ma Y, Wang J, Cao B. Role of long non-coding RNA H19 in therapy resistance of digestive system cancers. Mol Med 2021;27:1. [PMID: 33402118 DOI: 10.1186/s10020-020-00255-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Tian J, Luo B, Wang F. Identification of Three Prognosis-Related Differentially Expressed lncRNAs Driven by Copy Number Variation in Thyroid Cancer. Journal of Immunology Research 2022;2022:1-18. [DOI: 10.1155/2022/9203796] [Reference Citation Analysis]
44 Zhang H, Lu B. The Roles of ceRNAs-Mediated Autophagy in Cancer Chemoresistance and Metastasis. Cancers (Basel) 2020;12:E2926. [PMID: 33050642 DOI: 10.3390/cancers12102926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
45 Li B, Jiang J, Assaraf YG, Xiao H, Chen Z, Huang C. Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. Drug Resistance Updates 2020;53:100720. [DOI: 10.1016/j.drup.2020.100720] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
46 Cohen L, Assaraf YG, Livney YD. Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment. Pharmaceutics 2021;14:88. [PMID: 35056984 DOI: 10.3390/pharmaceutics14010088] [Reference Citation Analysis]
47 Bi H, Shang Z, Jia C, Wu J, Cui B, Wang Q, Ou T. LncRNA RNF144A-AS1 Promotes Bladder Cancer Progression via RNF144A-AS1/miR-455-5p/SOX11 Axis. Onco Targets Ther 2020;13:11277-88. [PMID: 33177836 DOI: 10.2147/OTT.S266067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
48 Zhang Z, Bao Z, Gao P, Yao J, Wang P, Chai D. Diverse Roles of F-BoxProtein3 in Regulation of Various Cellular Functions. Front Cell Dev Biol 2022;9:802204. [DOI: 10.3389/fcell.2021.802204] [Reference Citation Analysis]
49 Wang B, Deng Y, Jin J, Wu Y, Shen L. Long Noncoding RNA LIT3527 Knockdown induces Apoptosis and Autophagy through inhibiting mTOR pathway in Gastric Cancer Cells. J Cancer 2021;12:4901-11. [PMID: 34234860 DOI: 10.7150/jca.58185] [Reference Citation Analysis]
50 Wang K, Hu YB, Zhao Y, Ye C. LncRNA ANRIL Regulates Ovarian Cancer Progression and Tumor Stem Cell-Like Characteristics via miR-324-5p/Ran Axis. Onco Targets Ther 2021;14:565-76. [PMID: 33500630 DOI: 10.2147/OTT.S273614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]